Product References
A Local and Abscopal Effect Observed with Liposomal Encapsulation of Intratumorally Injected Oncolytic Adenoviral Therapy.
Cancers
Dong T,Shah JR,Phung AT,Larson C,Sanchez AB,Aisagbonhi O,Blair SL,Oronsky B,Trogler WC,Reid T,Kummel AC
14-0195-82 was used in Immunohistochemistry-immunofluorescence to evaluate the in vivo therapeutic efficacy of oncolytic serotype 5 adenovirus TAV255 in CAR-deficient tumors.
Mon Jun 12 00:00:00 EDT 2023
Expansion of interferon inducible gene pool via USP18 inhibition promotes cancer cell pyroptosis.
Nature communications
Arimoto KI,Miyauchi S,Troutman TD,Zhang Y,Liu M,Stoner SA,Davis AG,Fan JB,Huang YJ,Yan M,Glass CK,Zhang DE
14-0195-82 was used in Immunohistochemistry (Frozen), Immunohistochemistry (Paraffin) to show that USP18 suppression not only enhances expression of canonical IFN-stimulated genes (ISGs), but also activates the expression of a set of atypical ISGs and NF-κB target genes, including genes such as Polo like kinase 2 (PLK2), that induce cancer pyroptosis.
Tue Jan 17 00:00:00 EST 2023
Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic model.
Journal for immunotherapy of cancer
Shankara Narayanan JS,Hayashi T,Erdem S,McArdle S,Tiriac H,Ray P,Pu M,Mikulski Z,Miller A,Messer K,Carson D,Schoenberger S,White RR
14-0195-82 was used in Immunohistochemistry (Frozen), Immunohistochemistry (Paraffin) to generate meaningful therapeutic immune effects by combining IRE with local (intratumoral) delivery of a CD40 agonistic antibody (CD40Ab).
Sun Jan 01 00:00:00 EST 2023
Deficiency for SAMHD1 activates MDA5 in a cGAS/STING-dependent manner.
The Journal of experimental medicine
Schumann T,Ramon SC,Schubert N,Mayo MA,Hega M,Maser KI,Ada SR,Sydow L,Hajikazemi M,Badstübner M,Müller P,Ge Y,Shakeri F,Buness A,Rupf B,Lienenklaus S,Utess B,Muhandes L,Haase M,Rupp L,Schmitz M,Gramberg T,Manel N,Hartmann G,Zillinger T,Kato H,Bauer S,Gerbaulet A,Paeschke K,Roers A,Behrendt R
14-0195-82 was used in Immunohistochemistry to find that the chronic interferon response in SAMHD1-deficient mice was driven by the MDA5/MAVS pathway but required functional priming through the cGAS/STING pathway.
Mon Jan 02 00:00:00 EST 2023
Comparative analysis of the immune response to RFA and cryoablation in a colon cancer mouse model.
Scientific reports
Mauda-Havakuk M,Hawken NM,Owen JW,Mikhail AS,Saxena A,Karim B,Wakim PG,Pritchard WF,Karanian JW,Wood BJ
14-0195-82 was used in Immunohistochemistry to investigate and compare the immune responses to radiofrequency ablation (RFA) and cryoablation (CRA) in a colon cancer mouse model, revealing differences in the modulation of immune cells and cytokine profiles induced by these two ablation techniques.
Sat Oct 29 00:00:00 EDT 2022
Comparative analysis of the immune response to RFA and cryoablation in a colon cancer mouse model.
Scientific reports
Mauda-Havakuk M,Hawken NM,Owen JW,Mikhail AS,Saxena A,Karim B,Wakim PG,Pritchard WF,Karanian JW,Wood BJ
14-0195-82 was used in Immunohistochemistry to investigate and compare the immune responses to radiofrequency ablation (RFA) and cryoablation (CRA) in a colon cancer mouse model, revealing differences in the modulation of immune cells and cytokine profiles induced by these two ablation techniques.
Sat Oct 29 00:00:00 EDT 2022
Host CLIC4 expression in the tumor microenvironment is essential for breast cancer metastatic competence.
PLoS genetics
Sanchez VC,Yang HH,Craig-Lucas A,Dubois W,Carofino BL,Lack J,Dwyer JE,Simpson RM,Cataisson C,Lee MP,Luo J,Hunter KW,Yuspa SH
14-0195-82 was used in Immunohistochemistry to show that CLIC4 expression in human breast cancers may serve as a prognostic biomarker; therapeutic targeting of CLIC4 could reduce primary tumor viability and host metastatic competence.
Wed Jun 01 00:00:00 EDT 2022
Clonally expanded CD8 T cells characterize amyotrophic lateral sclerosis-4.
Nature
Campisi L,Chizari S,Ho JSY,Gromova A,Arnold FJ,Mosca L,Mei X,Fstkchyan Y,Torre D,Beharry C,Garcia-Forn M,Jiménez-Alcázar M,Korobeynikov VA,Prazich J,Fayad ZA,Seldin MM,De Rubeis S,Bennett CL,Ostrow LW,Lunetta C,Squatrito M,Byun M,Shneider NA,Jiang N,La Spada AR,Marazzi I
14-0195-82 was used in Immunohistochemistry (Frozen), Immunohistochemistry (Paraffin) to unravel disease mechanisms and as a potential biomarker of disease state.
Wed Jun 01 00:00:00 EDT 2022
Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model.
Molecular cancer research : MCR
El Meskini R,Atkinson D,Kulaga A,Abdelmaksoud A,Gumprecht M,Pate N,Hayes S,Oberst M,Kaplan IM,Raber P,Van Dyke T,Sharan SK,Hollingsworth R,Day CP,Merlino G,Weaver Ohler Z
14-0195-82 was used in Immunohistochemistry to suggest that an anti-PD-L1-mediated melanoma regression response requires not only an expansion of the TCR repertoire that is unique to individual mice, but also tumor access to the appropriate TCRs.
Sun Aug 01 00:00:00 EDT 2021
CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells.
iScience
Qadir AS,Guégan JP,Ginestier C,Chaibi A,Bessede A,Charafe-Jauffret E,Macario M,Lavoué V,Rouge TM,Law C,Vilker J,Wang H,Stroup E,Schipma MJ,Bridgeman B,Murmann AE,Ji Z,Legembre P,Peter ME
14-0195-82 was used in Immunohistochemistry to demonstrate that in addition to its tumor and metastasis promoting activities, CD95 expression by tumor cells can exert immune suppressive activities on NK cells, providing a new target for immune therapy.
Fri Nov 19 00:00:00 EST 2021
Retinoblastoma Inactivation Induces a Protumoral Microenvironment via Enhanced CCL2 Secretion.
Cancer research
Li F,Kitajima S,Kohno S,Yoshida A,Tange S,Sasaki S,Okada N,Nishimoto Y,Muranaka H,Nagatani N,Suzuki M,Masuda S,Thai TC,Nishiuchi T,Tanaka T,Barbie DA,Mukaida N,Takahashi C
14-0195 was used in Immunohistochemistry on paraffin embedded tissues to show that inactivation of the tumour suppressor retinoblastoma leads to a protumoral microenvironment via an increase in the secretion of the chemoattractant CCL2.
Thu Aug 01 00:00:00 EDT 2019
PD-1 Blockade Overcomes Adaptive Immune Resistance in Treatment with Anchored-GM-CSF Bladder Cancer Cells Vaccine.
Journal of Cancer
Zhang X,Shi X,Li J,Mo L,Hu Z,Gao J,Wu S,Long Z
Published figure using CD8a monoclonal antibody (Product # 14-0195-82) in Immunohistochemistry (PFA fixed)
Thu Oct 01 00:00:00 EDT 2020
PD-1 Blockade Overcomes Adaptive Immune Resistance in Treatment with Anchored-GM-CSF Bladder Cancer Cells Vaccine.
Journal of Cancer
Zhang X,Shi X,Li J,Mo L,Hu Z,Gao J,Wu S,Long Z
Published figure using CD8a monoclonal antibody (Product # 14-0195-82) in Immunohistochemistry (PFA fixed)
Thu Oct 01 00:00:00 EDT 2020
Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer.
Journal for immunotherapy of cancer
Pennock ND,Martinson HA,Guo Q,Betts CB,Jindal S,Tsujikawa T,Coussens LM,Borges VF,Schedin P
14-0195 was used in Immunohistochemistry on paraffin embedded tissues to implicate beneficial prophylactic use of ibuprofen during the pro-tumorigenic window of mammary gland involution.
Mon Oct 01 00:00:00 EDT 2018
DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer.
Nature communications
Luo N,Nixon MJ,Gonzalez-Ericsson PI,Sanchez V,Opalenik SR,Li H,Zahnow CA,Nickels ML,Liu F,Tantawy MN,Sanders ME,Manning HC,Balko JM
14-0195 was used in Immunohistochemistry-immunofluorescence to demonstrate up regulation of MHC-1 expression in human breast cancer in response to hypomethylating agent guadecitabine to aid anti-tumour immunity.
Tue Jan 16 00:00:00 EST 2018
DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer.
Nature communications
Luo N,Nixon MJ,Gonzalez-Ericsson PI,Sanchez V,Opalenik SR,Li H,Zahnow CA,Nickels ML,Liu F,Tantawy MN,Sanders ME,Manning HC,Balko JM
14-0195 was used in Immunohistochemistry-immunofluorescence to demonstrate up regulation of MHC-1 expression in human breast cancer in response to hypomethylating agent guadecitabine to aid anti-tumour immunity.
Tue Jan 16 00:00:00 EST 2018